Fulcrum Therapeutics Inc. (FULC) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
November 10, 2020 7:00 AM ESTReDUX4 trial progressing; full data with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) expected in 2Q 2021
 On track to begin dosing Phase 1 trial with FTX-6058 for sickle cell disease before YE 2020
 Cash runway into 2Q 2022
 Key appointments to management team
Conference call scheduled for 8:00 a.m. ET today
CAMBRIDGE, Mass., Nov. 10,... More
